INVA · Categories · M&A
INVA - Mergers and acquisitions
Innoviva Inc. (INVA) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for INVA
- Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressRoyalties at $65.6 million in the third quarter of 2022, compared to $65.7 million in the same quarter of 2021, for RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® Announced new $100.0 million share repurchase program Completed the sale of 15% ownership interest in Theravance Respiratory Company ("TRC") to Royalty Pharma Completed acquisition of the remaining approximately 40% equity of Entasis Therapeutics Holdings Inc. ("Entasis") Completed acquisition of La Jolla Pharmaceutical Company ("La Jolla") Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results
- Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 MillionFurther diversifies Royalty Pharma's portfolio with market-leading respiratory therapyExpected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (NASDAQ:TBPH) and Innoviva, Inc. (NASDAQ:INVA) for $1.31 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones. The acquisition is expected to close within ten business days. Trelegy, marketed by GSK, is a combination of an inhaled corticosteroi
- Innoviva to Acquire La Jolla Pharmaceutical CompanyAcquisition to strengthen Innoviva's infectious disease and hospital portfolio with addition of GIAPREZA® and XERAVA® Innoviva, Inc. (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (NASDAQ:LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume-